Brazil · Delayed Price · Currency is BRL Ascendis Pharma Statistics
Total Valuation
Ascendis Pharma has a market cap or net worth of BRL 92.74 billion. The enterprise value is 90.46 billion.
| Market Cap | 92.74B |
| Enterprise Value | 90.46B |
Important Dates
The next confirmed earnings date is Thursday, November 12, 2026.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +6.52% |
| Shares Change (QoQ) | +5.89% |
| Owned by Insiders (%) | 0.02% |
| Owned by Institutions (%) | 80.94% |
| Float | 65.64M |
Valuation Ratios
The trailing PE ratio is 19.21 and the forward PE ratio is 42.67.
| PE Ratio | 19.21 |
| Forward PE | 42.67 |
| PS Ratio | 14.96 |
| PB Ratio | 10.91 |
| P/TBV Ratio | 10.94 |
| P/FCF Ratio | 46.75 |
| P/OCF Ratio | 44.83 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 54.71, with an EV/FCF ratio of 45.61.
| EV / Earnings | 20.60 |
| EV / Sales | 13.75 |
| EV / EBITDA | 54.71 |
| EV / EBIT | 58.52 |
| EV / FCF | 45.61 |
Financial Position
The company has a current ratio of 2.99, with a Debt / Equity ratio of 0.31.
| Current Ratio | 2.99 |
| Quick Ratio | 2.23 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | 1.63 |
| Debt / FCF | 1.34 |
| Interest Coverage | 2.01 |
Financial Efficiency
Return on equity (ROE) is 118.78% and return on invested capital (ROIC) is 12.98%.
| Return on Equity (ROE) | 118.78% |
| Return on Assets (ROA) | 9.58% |
| Return on Invested Capital (ROIC) | 12.98% |
| Return on Capital Employed (ROCE) | 14.20% |
| Weighted Average Cost of Capital (WACC) | 7.35% |
| Revenue Per Employee | 5.21M |
| Profits Per Employee | 3.69M |
| Employee Count | 1,189 |
| Asset Turnover | 0.62 |
| Inventory Turnover | 0.30 |
Taxes
| Income Tax | -3.81B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.47% in the last 52 weeks. The beta is 0.49, so Ascendis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.49 |
| 52-Week Price Change | +34.47% |
| 50-Day Moving Average | 80.60 |
| 200-Day Moving Average | 53.38 |
| Relative Strength Index (RSI) | 63.29 |
| Average Volume (20 Days) | 159 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 4.43 |
Income Statement
In the last 12 months, Ascendis Pharma had revenue of BRL 6.20 billion and earned 4.39 billion in profits. Earnings per share was 4.92.
| Revenue | 6.20B |
| Gross Profit | 5.66B |
| Operating Income | 1.53B |
| Pretax Income | 579.10M |
| Net Income | 4.39B |
| EBITDA | 1.56B |
| EBIT | 1.53B |
| Earnings Per Share (EPS) | 4.92 |
Balance Sheet
The company has 4.81 billion in cash and 2.66 billion in debt, with a net cash position of 2.14 billion.
| Cash & Cash Equivalents | 4.81B |
| Total Debt | 2.66B |
| Net Cash | 2.14B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 8.50B |
| Book Value Per Share | 8.63 |
| Working Capital | 5.48B |
Cash Flow
In the last 12 months, operating cash flow was 2.07 billion and capital expenditures -85.18 million, giving a free cash flow of 1.98 billion.
| Operating Cash Flow | 2.07B |
| Capital Expenditures | -85.18M |
| Depreciation & Amortization | 29.49M |
| Net Borrowing | -185.38M |
| Free Cash Flow | 1.98B |
| FCF Per Share | n/a |
Margins
Gross margin is 91.30%, with operating and profit margins of 24.70% and 70.84%.
| Gross Margin | 91.30% |
| Operating Margin | 24.70% |
| Pretax Margin | 9.34% |
| Profit Margin | 70.84% |
| EBITDA Margin | 25.16% |
| EBIT Margin | 24.70% |
| FCF Margin | 30.79% |
Dividends & Yields
Ascendis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -6.52% |
| Shareholder Yield | -6.52% |
| Earnings Yield | 5.21% |
| FCF Yield | 2.14% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ascendis Pharma has an Altman Z-Score of 8.97 and a Piotroski F-Score of 7.
| Altman Z-Score | 8.97 |
| Piotroski F-Score | 7 |